Development of Safer Non-Steroidal Antiinflammatory Drugs by Dual Inhibition of Cox-2 and 5-Lox

S. A. Khan*, Mohammad Imran, M. F. Arshad and Suresh Kumar

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard, New Delhi- 110 062 (India)

ABSTRACT:

Selective COX-2 inhibitors were believed to reduce the side effect profile of classical NSAIDs. Recent pharmacological studies have indicated certain controversies regarding the safety of selective COX-2 inhibitors as another important arachidonic acid pathway, 5-LOX pathway, is upregulated during COX inhibition. To combat these controversies a new strategy, dual inhibition of COX-2 and 5-LOX has been developed. This strategy constitutes a valuable alternative to classical NSAIDs and selective COX-2 inhibitors for the treatment of inflammatory diseases. This review article highlights the therapeutic interest of designing dual COX-2/5-LOX inhibitors along with the various chemical families of dual inhibitors.

KEYWORDS:

Pyridazinone; Anticonvulsant activity

Download this article as: 

Copy the following to cite this article: Khan S. A, Imran M, Arshad M. F, Kumar S. Development of Safer Non-Steroidal Antiinflammatory Drugs by Dual Inhibition of Cox-2 and 5-Lox. Orient J Chem 2004;20(2).

Copy the following to cite this URL: Khan S. A, Imran M, Arshad M. F, Kumar S. Development of Safer Non-Steroidal Antiinflammatory Drugs by Dual Inhibition of Cox-2 and 5-Lox. Orient J Chem 2004;20(2). Available from: http://www.orientjchem.org/?p=18483